Is a Change of Factor VIII Product a Risk Factor for the Development of a Factor VIII Inhibitor?

Thromb Haemost 1998; 80(06): 1036-1037
DOI: 10.1055/s-0037-1615413

Letters to the Editor

Schattauer GmbH

Trevor Baglin

¹Cambridge Comprehensive Care Centre for Haemophilia, Department of Haematology, Addenbrooke’s NHS Trust, Cambridge, UK

,

Emma Beacham

¹Cambridge Comprehensive Care Centre for Haemophilia, Department of Haematology, Addenbrooke’s NHS Trust, Cambridge, UK

References
1 Hoyer L. Why do so many haemophilia A patients develop an inhibitor?. Brit J Haem 1995; 90: 498-501.
2 Hay C, Ludlam C, Colvin B, Hill F, Preston F, Wasseem N, Bagnall R, Peake I, on behalf of the UK Haemophilia Centre Directors Organisation and Berntorp E, Mauser Bunschoten E, Fijnvandraat K, Kasper C, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A.. Thromb Haemost 1998; 79: 762-6.
3 Peerlinck K, Arnout J, Giles J, Saint-Remy J, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate.. Thromb Haemost 1993; 69: 115-8.
4 Rosendaal F, Nieuwenhuis H, van den Berg H, Heijboer H, Mauser-Bunschoten E, van der Meer J, Smit C, Strengers P, Briet E. and Dutch Hemophilia Study Group. A sudden increase in factor VIII inhibitor development in multi-transfused hemophilia A patients in the Netherlands.. Blood 1993; 81: 2180-6.
5 Wong V, Baglin T, Beacham E, Wight D, Petrik J, Alexander G. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus.. Brit J Haem 1998; 97: 343-7.